ArticleAntimicrobial agents and chemotherapy2006

Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.

Seth Hetherington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.